http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020171076-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d7625628087750eade3dbb0fb812e700 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-663 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-785 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-663 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-785 |
| filingDate | 2018-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6f34c45e86cd5ae9ac5bc7fdfa30a18 |
| publicationDate | 2020-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2020171076-A1 |
| titleOfInvention | Sevelamer for the treatment and/or prevention of aortic stenosis |
| abstract | A method of treating and/or preventing aortic stenosis in a patient in need thereof comprises administering to the patient a therapeutically effective amount of sevelamer or a pharmaceutically acceptable derivative, mixture or salt thereof (e.g. sevelamer hydrochloride or sevelamer carbonate). The method may attenuate or arrest the deposition of calcium phosphate crystals on the aortic valve of the patient. The method is applicable to patients who do not have hyperphosphatemia, including those having a serum phosphate level of 2.5 mg/d L to 4.5 mg/d L. |
| priorityDate | 2017-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 34.